The comparison of the effectiveness of lincocin® and azitro® in the treatment of covid-19-associated pneumonia: A prospective study

Journal of Population Therapeutics and Clinical Pharmacology

Volumn 27, Issue SP1, 2020, Pages 5-10

  Guvenmez, Oguz ^a   Keskin, Hüseyin ^b   Ay, Burak ^c   Birinci, Suayip ^d   Kanca, Muhammed Furkan ^c  

^a Tarsus Medical Park Hospital ^*  (Turkey)

^b MEDICAL PARK HOSPITAL   (Turkey)

^c CUKUROVA UNIVERSITY   (Turkey)

^d MINISTRY OF HEALTH   (Turkey)

Author keywords

Coronavirus; COVID 19; Medication; Pneumonia; Treatment

Indexed keywords

AZITHROMYCIN; AZITRO; LINCOMYCIN; ANTIINFECTIVE AGENT;

ADULT; AGED; ARTICLE; BODY TEMPERATURE; CLINICAL ARTICLE; CLINICAL OUTCOME; CONTROLLED STUDY; CORONAVIRUS DISEASE 2019; FEMALE; HOSPITALIZATION; HUMAN; LUNG LAVAGE; MALE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REAL TIME REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS PNEUMONIA; BETACORONAVIRUS; BRONCHOALVEOLAR LAVAGE FLUID; COMPLICATION; CORONAVIRUS INFECTION; MIDDLE AGED; PANDEMIC; RISK FACTOR; VERY ELDERLY; VIROLOGY;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; BETACORONAVIRUS; BRONCHOALVEOLAR LAVAGE FLUID; CORONAVIRUS INFECTIONS; FEMALE; HUMANS; LINCOMYCIN; MALE; MIDDLE AGED; PANDEMICS; PNEUMONIA, VIRAL; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 85086622972     PISSN: 17106222     EISSN: None     Source Type: Journal    
DOI: 10.15586/jptcp.v27iSP1.684     Document Type: Article

References (18)

1. Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents. 2020;55(3):105924. https://doi.org/10.1016/j.ijantimicag.2020.​105924
2. Wang L, Wang Y, Ye D, Liu Q. A review of the 2019 Novel Coronavirus (COVID-19) based on current evidence. Int J Antimicrob Agents. 2020:105948. https://doi.org/10.1016/j.ijantimi-cag.2020.​105948
3. Wu Z, McGoogan JM. Characteristics of and important lessons from the Coronavirus Disease 2019 (COVID-19) outbreak in China: Summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA – J Am Med Assoc. 2020;323(13):1239– 42. https://doi.org/10.1001/jama.2020.2648
4. Wan S, Xiang Y, Fang W, et al. Clinical features and treatment of COVID-19 patients in Northeast Chongqing. J Med Virol. 2020. https://doi.org/10.1002/jmv.25783 [Online ahead of print]
5. Hassan SA, Sheikh FN, Jamal S, Ezeh JK, Akhtar A. Coronavirus (COVID-19): A review of clinical features, diagnosis, and treatment. Cureus. 2020;12(3):e7355. https://doi.org/10.7759/​cureus.​7355
6. LINCOCIN® (lincomycin HCl) | Pfizer Medical Information – US [Internet]. [cited 2020 Apr 10]. Available from: https://www.pfizermedicalinfor-mation.com/en-us/lincocin
7. Lincocin – FDA prescribing information, side effects and uses [Internet]. [cited 2020 Apr 10]. Available from: https://www.drugs.com/pro/linco-cin.html
8. Azithromycin (Systemic) (Professional Patient Advice) – Drugs.com [Internet]. [cited 2020 Apr 10]. Available from: https://www.drugs.com/ppa/azithromycin-systemic.html
9. Azithromycin – Wikipedia [Internet]. [cited 2020 Apr 10]. Available from: https://en.wikipedia.org/wiki/Azithromycin
10. Gautret P, Lagier J-C, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020:105949. https://doi.org/10.1016/j. ijantimicag.2020.105949
11. Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020;14(1):72–3. https://doi.org/10.5582/bst.2020.01047
12. Molina JM, Delaugerre C, Goff J Le, et al. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloro-quine and azithromycin in patients with severe COVID-19 infection. Médecine Mal Infect. 2020;50(4):384. ​https://doi.org/10.1016/j.medmal.2020.03.006
13. Chen J, Liu D, Liu L, et al. A pilot study of hydroxy-chloroquine in treatment of patients with common coronavirus disease-19 (COVID-19). J Zhejiang Univ (Med Sci). 2020;49(February):1–10. https://doi.org/10.3785/j.issn.1008-9292.2020.03.03
14. Li JW, Xin ZT, Wang XW, Zheng JL, Chao FH. Mechanisms of inactivation of hepatitis a virus in water by chlorine dioxide. Water Res. 2004;38(6):1514–19. https://doi.org/10.1016/j.watres.2003.12.021
15. Engelbrecht RS, Weber MJ, Salter BL, Schmidt CA. Comparative inactivation of viruses by chlo-rine. Appl Environ Microbiol. 1980;40(2):249–56. https://doi.org/10.1128/aem.40.2.249-256.1980
16. Morokutti-Kurz M, Graf C, Prieschl-Grassauer E. Amylmetacresol/2,4-dichlorobenzyl alcohol, hexyl-resorcinol, or carrageenan lozenges as active treatments for sore throat. Int J Gen Med. 2017;10:53–60. https://doi.org/10.2147/IJGM.S120665
17. Oxford JS, Lambkin R, Gibb I, Balasingam S, Chan C, Catchpole A. A throat lozenge contain-ing amyl meta cresol and dichlorobenzyl alcohol has a direct virucidal effect on respiratory syncy-tial virus, influenza A and SARS-CoV. Antivir Chem Chemother. 2005;16(2):129–34. https://doi. org/10.1177/095632020501600205
18. Rabenau HF, Kampf G, Cinatl J, Doerr HW. Efficacy of various disinfectants against SARS coronavirus. J Hosp Infect. 2005;61(2):107–11. https://doi.org/10.1016/j.jhin.2004.12.023